Abstract
Data from the CNSR III Study (The Third China National Stroke Registry), a total of 9600 participants were included in this study who underwent transthoracic echocardiography and brain magnetic resonance imaging. Our study demonstrated a strong association between left ventricular hypertrophy(LVH) and different neuroimaging markers of cerebral small vascular disease in patient with ischemic stroke. Concentric hypertrophy was associated with DWMH(deep white matter hyperintensity),EPVS (enlarged perivascular space),Lacune, brain atrophy, and CMBs(cerebral microbleeds), but not PVWMH(periventricular white matter hyperintensity). Eccentric hypertrophy was associated with DWMH,EPVS-CS(enlarged perivascular space in centrum semioval), Lacune, CMBs, but not PVWMH, EPVS-BG(enlarged perivascular space in basal ganglia), or brain atrophy.The results remained stable after adjustment for conventional covariates. There were some variance in two subtypes of LVH, especially in people with DWMH or EPVS-CS, eccentric LVH seems to have a higher risk than concentric LVH.
Background Some clinical special cardiovascular diseases have a certain associationwith the occurrence and development of cerebral small vessel disease(CSVD). Left ventricular hypertrophy (LVH) as a subclinical heart damage preceded heart failure is considered to be a risk factor for CSVD [2.3]. However, the precise relationship of LVH and CSVD is unclear.
Methods Patients with acute ischaemic stroke or transient ischaemic attack in China from the registric survey of the CNSR-III (The Third China National Stroke Registry) from August 2015 to March 2018 were included in present study.The markers of CSVD on magnetic resonance imaging, including white matter hypertintensity, perivascular space, lacunes, cerebral microbleeds, and brain atrophy, were assessed at baseline survey.Participants were divided into 4 groups according to relative wall thickness and left ventricular mass index assesed by transthoracic echocardiography. The association of left ventricular geomatric patterns with CSVD imaging markers was analyzed using ordinary or binary logistic regression models.
Results A total of 9600 participants were included in this study. The mean age of the participants was 61.9+11.2 years, and 6558(68.3%) were men.Compared with normal heart geometry, concentric hypertrophy had higher risk of deep white matter hyperintensity(DWMH)(odds ratio [OR]:1.54;95% confidence interval [CI]:1.16-2.04), enlarged perivascular space in basal gangalia(EPVS-BG) (OR:1.26; 95%CI:1.08-1.46), enlarged perivascular space in centrum semiovale(EPVS-CS) (OR:1.16; 95%CI:1.01-1.33), lacune (OR:1.45; 95%CI:1.26-1.67), brain atrophy (OR:1.42; 95%CI:1.20-1.69), but not periventricular white matter hyperintensity(PVWMH) after adjustment for covariates. Further, we did not found the association between eccentric heart hypertrophy and PVWMH, EPVS-BG and brain atrophy.
Conclusions In this ischemic stroke registry,we found a possible association between LVH and CSVD imaging markers at different sites, neither concentric nor eccentric heart hypertrophy was associated with PVWMH, that was independent of hypertension and other traditional vascular risk factors.
Graphical Abstract A graphic abstract is available for this article
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Natural Science Foundation of China (No. 81825007), Beijing Outstanding Young Scientist Program (No. BJJWZYJH01201910025030), Youth Beijing Scholar Program(No.010), Beijing Talent Project - Class A: Innovation and Development (No. 2018A12), "National Ten-Thousand Talent Plan"- Leadership of Scientific and Technological Innovation, National Key R&D Program of China (No. 2017YFC1307900, 2017YFC1307905, 2016YFC0901002).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (F.Y., Z.L., Yongjun Wang, Yilong Wang). China National Clinical Research Center for Neurological Diseases, Beijing, China(F.Y., H.Y., Y.P., J.J., X.M., Y.J., Z.L., H.L., Yongjun Wang, Yilong Wang). Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China(F.Y., Yongjun Wang, Yilong Wang).Chinese Institute for Brain Research, Beijing(Z.L., Yilong Wang).National Center for Neurological Diseases(Yilong Wang).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.
